Legislation introduced in the U.S. Senate in November, informally called the “Better FDA Act of 2025,” is perhaps a bit misleading. While it involves the Food and Drug Administration (“FDA”), the full title of S. 3122—introduced on November 6—is actually “The Better Food Disclosure Act of 2025,” designed to amend the federal Food, Drug, and Cosmetic Act (“FDCA”) regarding food substances generally recognized as safe (“GRAS”).
Introduction
Hardly a day goes by when we don’t see some media report of health care providers experimenting with machine learning, and more recently with generative AI, in the context of patient care. The allure is obvious. But the question is, to what extent do health care providers need to worry about FDA requirements as they use AI?
Recent Updates
- When AI Becomes Part of Medicine: Why CMS’s AI Questions Matter Now
- Watch: Gender-Affirming Care: What Health Care Providers Need to Know About Federal Enforcement – Thought Leaders in Health Law
- Executive Order 14321 at One Year: Civil Commitment Policy Shifts and Provider Impact
- Watch: FDA’s 2026 Enforcement Priorities: What In-House Counsel Must Know – Thought Leaders in Health Law
- The Future of 340B: New Bills Offer Competing Solutions to Modernize the 340B Drug Discount Program